Khiron Life Sciences

Overview

Khiron Life Sciences operates like a pharmaceutical company, commercializing medical cannabis products, operating trauma treatment facilities and developing pharma-grade beauty products throughout Latin America. Khiron’s model focuses on the patient, fulfilling their needs and understanding their expectations. Khiron prides itself on the development of a safe, consistent and high-quality product which enhances wellbeing for body and mind.

Highlights


Highlights of their most recent developments are:

  • December 2017: The National Narcotics Fund in Colombia issued resolution 766 of 2017 registering Khiron Colombia for the national use, commercialization, distribution and possession of cannabis and its derivates for medical purposes.
  • May 2018: Khiron received INVIMA approval to commercialize CBD products for Colombian domestic sale and export. This approval positions Khiron as the first fully licensed medical cannabis company to receive approval from INVIMA for cannabinoid-based products.
  • June 2018: Khiron secured medical cannabis endorsements from two of the largest medical associations in Colombia. This includes The Colombian Association of Internal Medicine (ACMI) and the Colombian Association of Neurology (ACN).
  • Khiron has commercialized seven wellness products in Colombia with authorization from Colombia’s National Food and Drug Surveillance Institute (INVIMA) for the production and sale.
  • July 2018: Khiron appointed Vicente Fox to the board of directors. Fox is the former CEO of Coca Cola Mexico, the former President of Mexico and a significant advocate for the legalization of cannabis in Mexico.
  • October 2018: the Company announced the signing of a definitive agreement to acquire the Latin American Institute of Neurology and the Nervous System. ILANS has approximately 60 clinicians represents approximately 100,000 patients. ILANS generates approximately $10,000,000 in revenues and $1,800,000 in EBITDA multiples, as set forth in audited financial statements for financial year ended December 31, 2017.

Last updated: January, 2019

Corporate Information


Executive Team

  • Alvaro Torres
  • CEO
  • Darren Collins
  • CFO
  • Chris Naprawa
  • President


Why We Love it


We think Khiron knows where the puck is going. At a time when its competition is focusing on Europe, the company is targeting the budding Latin American market.

As its President, Chris Naprawa, said: “Do I want to be the 125th LP competing for exports into Germany? Or do I want to be the dominant player in a 620-million-person market?” Having spent years in Colombia, the company knows the landscape. Khiron offers cannabis-infused cosmeceuticals in a region where beauty products are in extremely high-demand. Inkwood Research found the Latin American beauty product market was worth $60 billion in 2017.

The company has already established itself in Mexico, Colombia, Chile and Peru. With access to nearly 68 million potential patients already, Khiron has the potential to dominate the emerging Latin American cannabis sphere.

Contact Information


Khiron Life Sciences
Investor Relations
Chris Naprawa
President
T: +1 416-705-1144
cnaprawa@investors.khiron.ca